Abstract
Mutations in DDR genes, most notably BRCA1/2 and have been predictive to respond to PARP inhibitors and other DNA-damaging systemic therapies. However, the reports of detected germline and somatic variants in other DDR-related genes in early-stage, untreated breast cancers is limited. Here we report variants identified in multiple DDR-related genes in patients with untreated TNBC and association with pathologic complete response (pCR).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
